OverviewSuggest Edit

OptiNose develops nasal drug delivery technologies and combination drug-device therapies. It offers liquid delivery and powder delivery devices based on Bi-Directional Exhalation Delivery Systems (EDS). The company focuses on the treatment of chronic rhinosinusitis, nasal polyps, and chronic sinusitis.
TypePublic
Founded2000
HQMorrisville, PA, US
Websiteoptinose.com

Latest Updates

Employees (est.) (Feb 2021)204(-7%)
Job Openings5
Revenue (FY, 2020)$49.1 M(+42%)
Share Price (Oct 2021)$2.8(-2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at OptiNose

Peter K. Miller

Peter K. Miller

Chief Executive Officer, Director
Ramy A. Mahmoud

Ramy A. Mahmoud

President and Chief Operating Officer
Keith Goldan

Keith Goldan

Chief Financial Officer
Victor Clavelli

Victor Clavelli

Chief Commercial Officer
Mike Marino

Mike Marino

Chief Legal Officer
Ramona Lloyd

Ramona Lloyd

Senior Vice President, Regulatory & Quality
Show more

OptiNose Office Locations

OptiNose has offices in Morrisville, Oslo and Swindon
Morrisville, PA, US (HQ)
1020 Stony Hill Rd #300
Oslo, NO
Gaustadalléen 21
Swindon, GB
Berkeley House, Hunts Rise
Show all (3)

OptiNose Financials and Metrics

OptiNose Revenue

OptiNose's revenue was reported to be $49.12 m in FY, 2020
USD

Revenue (Q1, 2021)

12.0m

Net income (Q1, 2021)

(26.1m)

EBIT (Q1, 2021)

(22.2m)

Market capitalization (22-Oct-2021)

150.3m

Closing stock price (22-Oct-2021)

2.8

Cash (31-Mar-2021)

116.0m

EV

159.9m
OptiNose's current market capitalization is $150.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

85.0k47.5m7.1m34.6m49.1m

Revenue growth, %

55782%

Cost of goods sold

1.6m5.3m7.5m

Gross profit

5.5m29.3m41.6m
Quarterly
USDQ3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

865.0k1.3m1.9m4.5m6.7m12.4m7.1m10.3m15.4m12.0m

Cost of goods sold

200.0k351.0k319.0k738.0k1.1m1.4m

Gross profit

665.0k923.0k1.6m3.7m5.6m11.0m

Gross profit Margin, %

77%72%83%84%84%89%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

15.2m36.8m234.9m201.0m147.2m144.2m

Accounts Receivable

448.0k384.0k46.0k2.3m13.6m23.4m

Prepaid Expenses

1.3m2.2m

Inventories

2.0m7.1m3.5m9.0m
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

49.4m209.8m245.0m221.5m171.3m144.0m125.5m148.5m125.3m143.1m116.0m

Accounts Receivable

231.0k2.0m3.7m2.9m5.8m9.3m10.7m11.7m14.1m17.5m18.0m

Prepaid Expenses

438.0k1.4m2.2m1.9m3.8m3.0m3.2m3.8m3.4m2.5m3.7m

Inventories

241.0k3.6m5.0m7.0m5.7m4.3m4.4m5.7m6.1m9.3m12.7m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(28.3m)22.6m(48.9m)(106.7m)(110.1m)(99.8m)

Depreciation and Amortization

164.0k539.0k1.1m1.5m

Inventories

(2.0m)(4.7m)3.8m(5.4m)

Accounts Payable

450.0k(130.0k)392.0k3.2m(3.9m)2.2m
Quarterly
USDQ3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

28.2m(29.4m)(30.6m)(55.2m)(80.3m)(28.9m)(56.3m)(85.1m)(28.9m)(54.7m)(75.9m)(26.1m)

Depreciation and Amortization

104.0k156.0k172.0k325.0k269.0k592.0k878.0k309.0k563.0k1.0m165.0k

Inventories

(241.0k)(1.5m)(2.7m)(4.7m)1.4m2.8m2.8m(2.2m)(2.6m)(5.8m)(3.6m)

Accounts Payable

(524.0k)(574.0k)3.7m2.9m2.6m584.0k(4.3m)(1.9m)2.1m253.0k2.8m2.6m
USDFY, 2015

Financial Leverage

-0.1 x
Show all financial metrics

OptiNose Operating Metrics

Jun, 2017

Patents (US)

43

Patents Pending (US)

35

Trademarks (US)

3
Show all operating metrics

OptiNose Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

OptiNose Online and Social Media Presence

Embed Graph

OptiNose News and Updates

Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020

Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis

Company Expects Top-Line Results in First Quarter 2022

Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million

Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020

Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry

Co-founder and Chief Scientific Officer of Optinose AS honored for his invention of the technology used in the Optinose Exhalation Delivery System Co-founder and Chief Scientific Officer of Optinose AS honored for his invention of the technology used in the Optinose Exhalation Delivery System

Optinose to Present at the Jefferies Virtual Healthcare Conference

YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the J…

Optinose Reports First Quarter 2021 Financial Results and Operational Updates

Company reports first quarter total revenue of $12.0 million
Show more

OptiNose Blogs

New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day

New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 in 4 Americans With Nasal Congestion Experience Symptoms Almost Every Day Content Import Tue, 04/27/2021 - 06:01 New Harris Survey Reveals Chronic Nasal Congestion Is Surprisingly Widespread: Nearly 1 i…

Optinose to Present at the Needham Virtual Healthcare Conference

YARDLEY, Pa. , April 12, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Content Import Mon, 12/21/2020 - 10:00 Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 21, 2020 at 10:00 AM EST This release is a backfill from a News …

Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights

Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights Content Import Thu, 11/05/2020 - 07:03 Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights November 5, 2020 at 7:00 AM EST This releas…

Optinose Announces Reporting Date for Second Quarter 2020 Financial Results

Optinose Announces Reporting Date for Second Quarter 2020 Financial Results Content Import Thu, 07/30/2020 - 16:02 Optinose Announces Reporting Date for Second Quarter 2020 Financial Results July 30, 2020 at 4:01 PM EDT This release is a backfill from a News W…

Optinose names Catherine E. Owen as Director

Optinose names Catherine E. Owen as Director Content Import Wed, 07/29/2020 - 16:02 Optinose names Catherine E. Owen as Director July 29, 2020 at 4:01 PM EDT This release is a backfill from a News Wire General YARDLEY, Pa., July 29, …
Show more

OptiNose Frequently Asked Questions

  • When was OptiNose founded?

    OptiNose was founded in 2000.

  • Who are OptiNose key executives?

    OptiNose's key executives are Peter K. Miller, Ramy A. Mahmoud and Keith Goldan.

  • How many employees does OptiNose have?

    OptiNose has 204 employees.

  • What is OptiNose revenue?

    Latest OptiNose annual revenue is $49.1 m.

  • What is OptiNose revenue per employee?

    Latest OptiNose revenue per employee is $240.8 k.

  • Who are OptiNose competitors?

    Competitors of OptiNose include Veloxis Pharmaceuticals, Chiasma and Intersect ENT.

  • Where is OptiNose headquarters?

    OptiNose headquarters is located at 1020 Stony Hill Rd #300, Morrisville.

  • Where are OptiNose offices?

    OptiNose has offices in Morrisville, Oslo and Swindon.

  • How many offices does OptiNose have?

    OptiNose has 3 offices.